SI-BONE, Inc. (SIBN) witnessed a remarkable 9.39% surge in its stock price on Tuesday, driven by robust fourth-quarter financial results and a strong outlook for 2025. The medical device company specializing in musculoskeletal disorders of the sacropelvic anatomy reported record fourth-quarter worldwide revenue of $49 million, up 26% year-over-year, driven by strong demand for its innovative product portfolio.
The company achieved a significant milestone by delivering positive adjusted EBITDA of $1.9 million in the fourth quarter, marking its first-ever quarterly profit. For the full year 2024, SI-BONE's adjusted EBITDA loss narrowed by over 70% to $5.1 million, highlighting the scalability of its business model and progress towards generating positive free cash flow.
With new product launches like Granite 9.5 and TNT exceeding adoption expectations and continued momentum in its core SI joint fusion business, SI-BONE is well-positioned for sustained growth. The company guided for 2025 worldwide revenue of $193.5 million to $195.5 million, representing year-over-year growth of approximately 16% to 17%, and expects to achieve positive adjusted EBITDA for the full year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.